Delivery Order SPE2DB24D2101-SPE2DB25FKPCH
- Not listed
- The Defense Logistics Agency awarded a $3,418.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of DUPIXENT 200 mg/1.14 ml pen injectors, with an ultimate completion date of August 12, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA Troop Support Medical. The product will be performed at the contractor's location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors valued at $7,550.30 under a firm fixed price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside competitive award. AmerisourceBergen will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $5,001.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside contract represents a delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $8,931.71 to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pen auto-injectors (2 mL) on September 2, 2025, with completion targeted for September 3, 2025. This non-competitive, firm fixed-price delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $26,202.83. The contract, awarded on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing DLA contract vehicle. DUPIXENT (dupilumab) is a prescription biologic medication used to treat moderate-to-severe atopic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen injectors, valued at $6,777.99, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a continuation of the company's ongoing pharmaceutical supply relationship with the federal government. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a $8,920.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen (2 ml) pharmaceutical supplies with an ultimate completion date of July 21, 2025. This non-set-aside, competitively awarded contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through December 2026. The place of performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,862.39 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a $14,397.15 delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen auto-injectors. The contract, finalized on August 12, 2025, with completion targeted for August 13, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award through open solicitation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKPCHDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,747.93 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform at its corporate office location. This delivery order falls under the company's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The company holds a significant position within the DLA's Medical Supply Chain and serves multiple federal healthcare customers, including the Defense Health Agency and U.S. Coast Guard. DUPIXENT (dupilumab) is a specialty biologic medication used for treating moderate-to-severe atopic dermatitis, moderate-to-severe asthma, and chronic rhinosinusitis with nasal polyposis. This delivery order represents routine pharmaceutical resupply operations consistent with AmerisourceBergen Drug Corp's extensive portfolio of competitively awarded federal contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.7k | 9/2/25 |